2022-03-20-世界卫生组织-Influenza_Update_N°_415_13页_1mb

报告摘要

Influenza Update Summary (21 March 2022)

Overview

This update provides influenza surveillance data up to 6 March 2022, noting that COVID-19 pandemic impacts may affect health-seeking behaviors, surveillance routines, and testing capabilities, complicating data interpretation.

Impact of COVID-19

COVID-19 measures likely reduced influenza transmission and altered surveillance systems.
Influenza activity remained low globally after a peak in late 2021, with activity decreasing in many areas.

Global Influenza Activity

Influenza activity was low overall.
Viruses detected included influenza A(H3N2), A(H1N1)pdm09, and B/Victoria lineage, with A(H3N2) predominant in several regions.
Recommendations include preparing for co-circulation with SARS-CoV-2, enhancing integrated surveillance, increasing vaccination rates, and using differential diagnosis to identify influenza in high-risk groups.

Regional Details

North America: Activity increased slightly but remained below pre-pandemic levels, dominated by influenza A(H3N2); RSV activity low.
Europe: Activity increased with influenza A(H3N2) predominant; very low RSV activity.
East Asia: Activity increased slightly, mainly in China with influenza B/Victoria lineage; Mongolia and Korea reported elevated ILI or RSV.
Other Regions: Mostly low activity, with some increases in specific areas (e.g., Southern Asia, South-East Asia).

SARS-CoV-2 and Influenza Co-circulation

SARS-CoV-2 sentinel surveillance data included, with varying positivity rates across WHO regions.
WHO recommends integrated influenza and SARS-CoV-2 surveillance and campaigns to prepare for potential co-circulation.

Recommendations

Enhance influenza surveillance and reporting.
Step up influenza vaccination efforts.
Clinicians should consider influenza in differential diagnosis and follow national guidelines for testing and treatment.
Further details on regional reports and data available from WHO sources.

Data and Reporting

Based on FluNet data from 117 countries for influenza and 55 for SARS-CoV-2.
WHO GISRS laboratories tested over 367,148 specimens; 17,423 positive for influenza.
Data completeness varies due to COVID-19 disruptions.

展开完整摘要